| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6521260 | NOVARTIS | Carrier particles for use in dry powder inhalers |
Jan, 2016
(8 years ago) | |
| US6582678 | NOVARTIS | Carrier particles for use in dry powder inhalers |
Apr, 2018
(6 years ago) | |
| US6528678 | NOVARTIS | Phosgene-free process for preparing carbamates |
Apr, 2018
(6 years ago) | |
| US7229607 | NOVARTIS | Treatment of respiratory disease |
Apr, 2021
(3 years ago) | |
| US8029768 | NOVARTIS | Treatment of respiratory diseases |
Apr, 2021
(3 years ago) | |
| US8580306 | NOVARTIS | Particles for use in a pharmaceutical composition |
Jun, 2021
(2 years ago) | |
| US8048451 | NOVARTIS | Pharmaceutical compositions for inhalation |
Jun, 2021
(2 years ago) | |
| US8435567 | NOVARTIS | Pharmaceutical compositions of hydrophobic surface-modified active substance microparticles for inhalation |
Jun, 2021
(2 years ago) | |
| US8956661 | NOVARTIS | Method of making composite particles for use in pharmaceutical compositions and composite particles and compositions thereof |
Jun, 2021
(2 years ago) | |
| US9931304 | NOVARTIS | Method of making particles for use in a pharmaceutical composition |
Jun, 2021
(2 years ago) | |
| US8303991 | NOVARTIS | Method of making particles for use in a pharmaceutical composition |
Jun, 2021
(2 years ago) | |
| US9962338 | NOVARTIS | Method of making particles for use in a pharmaceutical composition |
Jun, 2021
(2 years ago) | |
| US7736670 | NOVARTIS | Method of making particles for use in a pharmaceutical composition |
Jun, 2021
(2 years ago) | |
| US8479730 | NOVARTIS | Inhaler device |
Oct, 2028
(4 years from now) | |
| US8182838 | NOVARTIS | Dry powder composition comprising co-jet milled particles for pulmonary inhalation |
Oct, 2028
(4 years from now) | |
Seebri is owned by Novartis.
Seebri contains Glycopyrrolate.
Seebri has a total of 15 drug patents out of which 13 drug patents have expired.
Expired drug patents of Seebri are:
- US6521260
- US6582678
- US6528678
- US7229607
- US8029768
- US8580306
- US8048451
- US8435567
- US8956661
- US9931304
- US8303991
- US9962338
- US7736670
Seebri was authorised for market use on 29 October, 2015.
Seebri is available in powder;inhalation dosage forms.
Seebri can be used as long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd).
The generics of Seebri are possible to be released after 20 October, 2028.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 29, 2018 |
Drugs and Companies using GLYCOPYRROLATE ingredient
Market Authorisation Date: 29 October, 2015
Treatment: Long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd)
Dosage: POWDER;INHALATION
SEEBRI family patents
